WeVote
Log In

Bill

Bill

SD 2055

An Act to promote transparency in prescription drug prices

194th Legislature (2025-2026) Introduced by Ed Kennedy

Massachusetts bill requiring prescription drug price transparency to improve consumer access to pricing information and inform policy decisions.

House concurred
0
WeVote Research Nonpartisan
Bill Summary · SD 2055

Legislative bill overview

SD 2055 proposes measures to increase transparency regarding prescription drug pricing in Massachusetts. The bill aims to provide consumers and policymakers with greater visibility into drug pricing mechanisms, potentially including manufacturer pricing data, pharmacy benefit manager (PBM) practices, or insurance plan costs.

Why is this important

Prescription drug prices in the United States are significantly higher than in other developed nations, creating financial hardship for patients and straining state budgets. Transparency measures can help identify pricing patterns, reduce information asymmetries between patients and providers, and inform future policy decisions about drug cost regulation.

Potential points of contention

  • Industry opposition: Pharmaceutical manufacturers and PBMs may resist disclosure requirements, citing proprietary business concerns and competitive disadvantages
  • Data scope ambiguity: Disagreement over which entities must disclose data (manufacturers, insurers, pharmacies), what specific information is required, and how broadly it applies
  • Implementation costs: Questions about administrative burden on healthcare entities and whether transparency alone addresses affordability without accompanying price controls

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.